# Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301

> **NCT02211508** · NA · TERMINATED · sponsor: **Cerephex Corporation** · enrollment: 236 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DEVICE:** RINCE

## Key facts

- **NCT ID:** NCT02211508
- **Lead sponsor:** Cerephex Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 236 (ACTUAL)
- **Why stopped:** Trial terminated Feb '15. Interim analysis results missed primary endpoint, intended signal not delivered in Tx arm, sham results as expected. No safety issues.
- **Last updated:** 2016-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211508, "Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02211508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*